Shaperon Inc.

Shaperon Inc. develops therapies based on GPCR19-inflammasome inhibitor platform and NanoMab antibody platform for immune diseases. It offers NuGel which blocks the root cause of atopic dermatitis that is in Phase 2 clinical trials; NuDifin that calms wound inflammation and accelerates the regeneration of tissue; NuRalin indicated for atopic dermatitis; NuAreatin for the treatment of alopecia areata. The company also provides NuCerin, a pill designed to reduce neuroinflammation; NuSepin, which alleviates excessive systemic inflammation; and NuPulin for the treatment of inflammation-driven pulmonary fibrosis. In addition, it offers Papiliximab, a NanoMab-based bispecific antibody that blocks PD-L1 and CD47 for leukemia treatment; Ovizumab, a tumor-specific immunotherapy; Regtizumab, an anti-tumor immunity; and Rbody, a NanoMabs’ small size which enables the creation of LNP-mRNA therapeutics. Further, the company provides RumiLua, a cosmeceutical ingredient to help prevent excessive skin responses while supporting the skin’s natural balance and overall condition. The company was founded in 2008 and is headquartered in Seoul, South Korea.